Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio Posts Double-Digit Q1 Organic Revenue Growth

NEW YORK, May 5 (GenomeWeb News) - Harvard Bioscience yesterday reported a 7.7-percent increase in first-quarter revenues, with organic revenue growth of 11.9 percent.

 

Revenues for the three months ended March 31, inched up to $17.4 million from $16.1 million in the comparable period of 2005. Excluding the impact of foreign exchange rate changes, however, revenue grew 11.9 percent compared to the same period in 2005, the company said.

 

The increase in revenues was "across various product lines, and was primarily attributed to an increase in demand for our pre-clinical testing products," Harvard Bio said in a statement.

 

Net income more than doubled to $540,000 from $202,000 in the first quarter of 2005.

 

Harvard Bioscience spent $751,000 on R&D in the first quarter, down slightly from $870,000 in the comparable period of 2005.

 

As of March 31, the company had cash and cash equivalents of $9.8 million, and an additional $2.1 million in discontinued operations.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.